Caza Tiffany N, Jhaveri Kenar D
Arkana Laboratories, 10810 Executive Center Drive #100, Little Rock, AR, USA.
Division of Kidney Diseases and Hypertension at Hofstra/Northwell and the Glomerular Center at Northwell Health, Lake Success, NY, USA.
Clin Kidney J. 2023 Feb 6;16(6):896-900. doi: 10.1093/ckj/sfad023. eCollection 2023 Jun.
Glomerular disease is an important complication in patients undergoing hematopoietic stem cell transplantation (HSCT), impacting approximately 1%-2% of all HSCT recipients and equating to 700-1400 cases per year worldwide. Development of kidney disease in HSCT recipients is often multifactorial and a kidney biopsy is required to identify the underlying disease etiology and pathology. While glomerular disease is an important toxicity following HSCT, there are few kidney biopsy studies examining this complication, with the majority being limited to small series and case reports. A range of glomerular diseases may occur in association with HSCT. The study by Yap . defines this disease spectrum, which includes (in descending order) thrombotic microangiopathy (38.7%), membranous nephropathy (25.8%), mesangial proliferative glomerulonephritis (12.9%), minimal change disease (9.7%), focal segmental glomerulosclerosis (9.7%) and membranoproliferative glomerulonephritis (3.2%). In this editorial, we summarize the study and prior studies looking at glomerular diseases associated with HSCT.
肾小球疾病是造血干细胞移植（HSCT）患者的重要并发症，影响着约1%-2%的HSCT受者，全球每年约有700-1400例。HSCT受者发生肾脏疾病通常是多因素的，需要进行肾活检以确定潜在的疾病病因和病理。虽然肾小球疾病是HSCT后的一种重要毒性反应，但很少有肾活检研究来探讨这一并发症，大多数研究仅限于小样本系列和病例报告。一系列肾小球疾病可能与HSCT相关。Yap等人的研究界定了这一疾病谱，其中包括（按降序排列）血栓性微血管病（38.7%）、膜性肾病（25.8%）、系膜增生性肾小球肾炎（12.9%）、微小病变病（9.7%）、局灶节段性肾小球硬化（9.7%）和膜增生性肾小球肾炎（3.2%）。在这篇社论中，我们总结了该研究以及之前关于与HSCT相关的肾小球疾病的研究。
